Protagenic Therapeutics (PTIX) chair adds 2,220 shares in open-market buy
Rhea-AI Filing Summary
Protagenic Therapeutics, Inc. director and executive chair Armen Garo H reported an open-market purchase of common stock. On 2026-08-11, he purchased 2,220 shares at $0.32 per share, bringing his directly held position to 34,199 common shares. The transaction was reported as a direct ownership purchase and not under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,220 shares
Net Buy
1 txn
Insider
ARMEN GARO H
Role
EXEC. CHAIR & PRINCIPAL OFF
Bought
2,220 shs ($710.40)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 2,220 | $0.32 | $710.40 |
Holdings After Transaction:
COMMON STOCK — 34,199 shares (Direct)
Key Figures
Shares purchased: 2,220 shares
Purchase price: $0.32 per share
Shares owned after transaction: 34,199 shares
3 metrics
Shares purchased
2,220 shares
Common stock bought on 2026-08-11
Purchase price
$0.32 per share
Price for 2,220 common shares on 2026-08-11
Shares owned after transaction
34,199 shares
Directly held PTIX common stock following the purchase
Key Terms
Form 4, Rule 10b5-1, open market or private transaction
3 terms
Form 4 regulatory
"reported this open-market purchase on a Form 4 insider report"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Rule 10b5-1 regulatory
"not identified as executed under a Rule 10b5-1 plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
open market or private transaction financial
"transaction code description notes a purchase in open market or private transaction"
FAQ
What insider transaction did PTIX report for Armen Garo H?
Armen Garo H reported a purchase of 2,220 PTIX common shares on 2026-08-11 at $0.32 per share, increasing his directly held stake to 34,199 shares according to the Form 4 disclosure.
Was the recent PTIX insider trade by Armen Garo H a buy or sell?
The reported PTIX insider trade was a buy. Armen Garo H purchased 2,220 common shares of Protagenic Therapeutics at $0.32 per share, with no sales reported in this Form 4 filing.
Was the PTIX insider purchase made under a Rule 10b5-1 trading plan?
The filing indicates the Rule 10b5-1 checkbox was not marked, so the reported purchase of 2,220 PTIX shares at $0.32 per share on 2026-08-11 is not identified as executed under a Rule 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
